Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Insmed Incorporated
Insmed Incorporated News
Insmed Incorporated Quantitative Score
About Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insmed Incorporated Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Insmed Incorporated Financials
Table Compare
Compare INSM metrics with: | |||
|---|---|---|---|
Earnings & Growth | INSM | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | INSM | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | INSM | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | INSM | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Insmed Incorporated Income
Insmed Incorporated Balance Sheet
Insmed Incorporated Cash Flow
Insmed Incorporated Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Insmed Incorporated Executives
| Name | Role |
|---|---|
| Mr. William H. Lewis J.D., M.B.A. | President, Chief Executive Officer & Chairman |
| Mr. Roger Adsett M.B.A. | Chief Operating Officer |
| Dr. Martina Flammer M.B.A., M.D. | Chief Medical Officer |
| Mr. John Drayton Wise M.B.A. | Consultant |
| Ms. Sara M. Bonstein M.B.A. | Chief Financial Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. William H. Lewis J.D., M.B.A. | President, Chief Executive Officer & Chairman | Male | 1969 | 2.12M |
| Mr. Roger Adsett M.B.A. | Chief Operating Officer | Male | 1969 | 1.26M |
| Dr. Martina Flammer M.B.A., M.D. | Chief Medical Officer | 1964 | 1.11M | |
| Mr. John Drayton Wise M.B.A. | Consultant | Male | 1975 | 1.11M |
| Ms. Sara M. Bonstein M.B.A. | Chief Financial Officer | Female | 1981 | 1.01M |
Insmed Incorporated Insider Trades
| Date | 21 Jul |
| Name | Bonstein Sara |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 3443 |
| Date | 21 Jul |
| Name | Bonstein Sara |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 11455 |
| Date | 21 Jul |
| Name | Bonstein Sara |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 15890 |
| Date | 21 Jul |
| Name | Bonstein Sara |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 17100 |
| Date | 21 Jul |
| Name | Bonstein Sara |
| Role | Chief Financial Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 32090 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 21 Jul | Bonstein Sara | Chief Financial Officer | Acquired | M-Exempt | 3443 |
| 21 Jul | Bonstein Sara | Chief Financial Officer | Acquired | M-Exempt | 11455 |
| 21 Jul | Bonstein Sara | Chief Financial Officer | Acquired | M-Exempt | 15890 |
| 21 Jul | Bonstein Sara | Chief Financial Officer | Acquired | M-Exempt | 17100 |
| 21 Jul | Bonstein Sara | Chief Financial Officer | Disposed | S-Sale | 32090 |